Policy Developments - The National Healthcare Security Administration (NHSA) held the first session of a series of discussions on supporting innovative drugs and medical devices, with over 20 representatives from pharmaceutical companies, research institutions, and medical organizations participating. The meeting emphasized the NHSA's commitment to supporting true innovation and the importance of a comprehensive value assessment for innovative products to enhance healthcare resource utilization and better serve public health [2]. Drug and Device Approvals - Shanghai Pharmaceuticals announced that its subsidiary's tranexamic acid injection has received approval from the National Medical Products Administration (NMPA) after passing the consistency evaluation for generic drugs. This drug is primarily used for various bleeding conditions caused by primary fibrinolysis [4]. - Huason Pharmaceutical received re-registration approval for three drugs from the Chongqing Drug Administration, including Ganqi Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets [5]. - Huiren Pharmaceutical's subsidiary received approval for the listing of methochlorpromazine hydrochloride raw materials, which are used for preventing postoperative nausea and vomiting, as well as treating nausea related to migraines and radiation therapy. Additionally, the subsidiary received a medical device registration certificate for a sterile, single-use syringe [6]. Capital Market Activities - ST Jingfeng announced the sale of a 51% stake in its subsidiary Jiangxi Yanhua Pharmaceutical to Jiangxi Shaoyang Pharmaceutical for a price of 142,500 yuan. Following this transaction, Jiangxi Yanhua will no longer be included in the company's consolidated financial statements [8]. Industry Events - Sichuan University West China Hospital successfully completed the first implanted brain-machine interface surgery in Western China for a patient with spinal cord injury, allowing the patient to control a mechanical hand using brain signals [10][11]. - Samsung Medical's subsidiary signed a procurement framework contract in Brazil worth approximately 341 million yuan, which represents 2.33% of the company's audited revenue for 2024 [12].

华仁药业股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司青岛华仁医疗用 品有限公司收到山东省药品监督管理局核准签发的"一次性使用无菌无芯杆溶药 注射器"的《医疗器械注册证》，现将相关情况公告如下： 一、医疗器械基本情况 证券代码：300110 证券简称：华仁药业 公告编号：2025-044 2、注册人住所：青岛市崂山区株洲路 187 号 3、生产地址：青岛市崂山区株洲路 187 号无菌医疗器械车间楼 4、产品名称：一次性使用无菌无芯杆溶药注射器 1、注册人名称：青岛华仁医疗用品有限公司 6、适用范围：与配药机配套使用，供抽取或配制药液用 7、注册证编号：鲁械注准 20252140434 8、注册分类：Ⅱ类 5、型号、规格：HRRY-A 10ml、HRRY-A 20ml、HRRY-A 30ml 等 特此公告。 本次取得一次性使用无菌无芯杆溶药注射器《医疗器械注册证》后，将进一 步丰富公司医疗器械产品线，提高公司医疗器械产品的综合竞争力，助力公司原 料药、 ...

关于全资子公司盐酸甲氧氯普胺原料药获得上市申请批准 通知书的公告 证券代码：300110 证券简称：华仁药业 公告编号：2025-043 华仁药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸甲氧氯普胺"《化学原料药上市申请批准通知书》（通知书编号：2025YS00581）。 现将相关情况公告如下： 一、原料药登记信息 1．通用名称：盐酸甲氧氯普胺 2．英文名/拉丁名：Metoclopramide Hydrochloride 3．化学原料药注册标准编号：YBY66742025 4．包装规格：5kg/袋/桶 5．申请事项：境内生产化学原料药上市申请 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 二、药品的其他情况 盐酸甲氧氯 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-042 华仁药业股份有限公司 关于持股 5%以上股东减持计划实施完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"公司"）于2025年6月3日披露了持股5%以 上股东华仁世纪集团有限公司（以下简称"华仁世纪集团"）《关于持股5%以上 股东减持计划预披露的公告》（公告编号：2025-036），华仁世纪集团计划自减 持计划公告之日起十五个交易日后的三个月内通过集中竞价交易方式减持不超 过公司总股本1%的股份，即不超过11,822,100股。 近日，公司收到华仁世纪集团《关于减持华仁药业股份计划实施结果的告知 函》，华仁世纪集团上述减持计划已实施完成。现将具体情况公告如下： 二、华仁世纪集团本次减持前后持股情况 | | | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | 股东 | 股份 | | | | | | 名称 | 性质 | 股数（股） | 占总股本 | 股数（股） | ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-041 | 股 A | 0.14 163.72 | | | | --- | --- | --- | --- | | | 通过证券交易所的集中交易  | | | | 本次权益变动方式（可多 选） | 通过证券交易所的大宗交易 □ | | | | | 其他 □ | | | | 3. | 本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 | | | | | 本次变动前持有股份 | | 本次变动后持有股份 | | 股份性质 | | | | | | 股数（万 占总股本比 股数（万股） | | 占总股本比例 | | | 股） | 例（%） | （%） | | 合计持有股份 | 9,529.7436 9,366.0236 | 8.06 | 7.92 | | 其中：无限售条件股份 | 9,529.7436 9,366.0236 | 8.06 | 7.92 | | 有限售条件股份 | 0 0 | 0 | 0 | | 4. 承诺、计划等履行情况 | | | | | |  否 | 是 | | | | 公司于 日披露了《关于持股 3 | 年 月 202 ...

Group 1 - CITIC Construction Investment has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 20 billion yuan [1] - Bluefocus Technology has received a loan commitment of up to 900 million yuan from CITIC Bank for stock repurchase [1] - Huaren Pharmaceutical's subsidiary has received approval for the listing of Bumetanide raw materials, which are used to treat severe heart failure and hypertension emergencies [3] Group 2 - Betta Pharmaceuticals has received approval for the listing of Enasidenib capsules in Macau, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer [4] - Juewei Food plans to use 110 million yuan of idle fundraising for cash management, with an expected annual yield of 1.00%-1.89% [6] - China Huadian has successfully completed the issuance of 1 billion yuan medium-term notes with a coupon rate of 1.95% [9] Group 3 - Fosun Pharma's subsidiary has received a GMP certificate from the Belgian Federal Agency for Medicines and Health Products for the production facilities of two monoclonal antibodies [11] - China Nuclear Engineering has signed a civil engineering contract for the Taishan Nuclear Power Units 3 and 4 [13] - Kanglongda has faced administrative regulatory measures from the Zhejiang Securities Regulatory Bureau due to the failure of performance commitment parties to fulfill compensation obligations [15] Group 4 - Gaoling Information has received three invention patent certificates in the second quarter, covering various technological fields [16] - Weimais plans to use 190 million yuan of excess fundraising to increase capital in its subsidiary for building a new energy vehicle powertrain production base [17] - Huazhong Technology has received a project designation notice from a leading eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [19] Group 5 - Madi Technology expects a net profit of 25 million to 27 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [19] - Dazhong Mining's subsidiary has obtained a mining license for the Zhouyoufang Iron Mine, increasing production capacity to 6.5 million tons per year [20] - Zhongguancun's subsidiary has had its application for the listing of Arolol hydrochloride tablets accepted by the National Medical Products Administration [21] Group 6 - Tianhong Co. has signed a property management contract worth 15 million yuan with a local company [22] - Dong'an Power has secured nine new market designation agreements in the second quarter, with a projected total sales volume of 1.5 million units [24] - Zhujiang Co. has appointed Zhao Kun as the new deputy general manager [25] Group 7 - Jinyi Industrial has won a bid for a project worth 335 million yuan from the China Railway Shanghai Bureau Group [26] - Kangchen Pharmaceutical has received a clinical trial notification for its innovative drug KC1086, aimed at treating advanced solid tumors [27] - Changhua Group has received a project designation notice from a new energy vehicle company, with an expected total sales amount of 970 million yuan [29] Group 8 - Lingxiao Pump Industry plans to use 60 million yuan of idle funds to purchase financial products [31] - Mould Technology has received a project designation for exterior parts from a well-known North American electric vehicle company, with an expected total sales of 1.236 billion yuan [34] - Fulongma has pre-bid for five sanitation service projects in June, with a total contract amount of 181 million yuan [35] Group 9 - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange [36] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [37] - Beilu Pharmaceutical's subsidiary has received approval for the listing of Iopamidol raw materials [38] Group 10 - Zhejiang Liming's shareholder plans to reduce their stake by up to 2.93% [39] - Zhejiang Liming's actual controller has committed not to reduce their holdings within a year [40] - SAIC Motor reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [41] Group 11 - Xinhongcheng expects a net profit increase of 50%-70% for the first half of 2025 [42] - Xianhe Co. plans to invest 11 billion yuan in a bamboo pulp paper integrated project [42] - Great Wall Motors reported a total vehicle sales of 569,800 units in the first half of 2025, a year-on-year increase of 1.81% [43] Group 12 - Dongfeng Co. received a government subsidy of 10 million yuan [44] - Zhongke Environmental Protection has acquired two water environmental companies in Guangxi for a total of 353 million yuan [45] - Anji Food's H-share public offering is priced at 60 Hong Kong dollars per share [46]

Core Viewpoint - Huaren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the listing of the raw material drug Bumetanide, which is indicated for severe heart failure, acute pulmonary edema, and adult hypertension, enhancing the company's product line and market competitiveness [1] Group 1 - The approval of Bumetanide will enrich the company's raw material drug product line [1] - The drug is effective for severe heart failure, acute pulmonary edema, and adult hypertension, showcasing its strong diuretic properties [1] - The approval is expected to boost the company's market sales and enhance its competitive edge [1] Group 2 - The development will support the synergistic growth of the company's raw material drugs, formulations, medical devices, and medical packaging sectors [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-040 华仁药业股份有限公司 关于全资子公司布美他尼原料药获得上市申请批准 1．通用名称：布美他尼 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 二、药品的其他情况 布美他尼适用于成人严重心力衰竭，包括急性肺水肿；成人高血压，在短期 内伴有危及生命的内脏疾病（高血压急症），尤其是在以下情况下：高血压脑病， 左心室失代偿伴肺水肿；成人心脏、肾脏、肝硬化引起的严重钠潴留。布美他尼 通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"布 美他尼"《化学原料药上市申请批准通知书》（通知书编号：2025YS00519）。现 将相关情况公告如下： 一、原料药登记信息 三、对公司的影响 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-039 华仁药业股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"公司"）根据《公司法》等相关规定，于 2025 年 6 月 23 日召开职工代表大会，会议选举王梦辰先生（简历详见附件）担任公司 第八届董事会职工代表董事，任期自本次职工代表大会审议通过之日起至公司第八 届董事会任期届满之日止。 王梦辰先生符合《公司法》等规定的职工代表董事任职资格和条件。王梦辰先 生担任职工代表董事后，公司董事会中兼任公司高级管理人员以及由职工代表担任 的董事人数总计不超过公司董事总数的二分之一。 特此公告。 华仁药业股份有限公司董事会 二〇二五年六月二十三日 附件：职工代表董事简历 王梦辰先生，1988 年 3 月出生，中国国籍，中共党员，无境外永久居留权， 硕士研究生学历，公司律师。2020 年至今，历任华仁药业风控经理，供应链部 副总监，董事会办公室副主任，现任综合管理部副部长。 王梦辰先生未持有公司股份，与公司控股股东、实际控制人、其他 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]